Aquestive Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Highlights

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to Aquestive Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Highlights

Aquestive Therapeutics (AQST) PT Raised to $24 at RBC Capital

November 7, 2018 7:09 AM EST

RBC Capital analyst Randall Stanicky raised the price target on Aquestive Therapeutics (NASDAQ: AQST) to $24.00 (from $23.00) while maintaining an Outperform rating following results.

Stanicky said pending Sympazan launch set to pave the way for lead product Libervant next year.

... More

Aquestive Therapeutics Inc. (AQST) Misses Q3 EPS by 16c

November 6, 2018 4:43 PM EST

Aquestive Therapeutics Inc. (NASDAQ: AQST) reported Q3 EPS of ($0.64), $0.16 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $13.3 million versus the consensus estimate of $14.24 million.

As of September 30, 2018, Aquestive's cash and cash equivalents were $64.0 million, as compared to $17.4 million as of... More